MedTrace Logo

STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

NCT05277285 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-01-13

No results posted yet for this study

Summary

The primary purpose is to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. A secondary purpose is to describe data on the clinical efficacy of administration of up to three doses of STS in critically ill patients with confirmed COVID-19.

Conditions

  • COVID-19
  • Virus Diseases
  • Corona Virus Infection

Interventions

DRUG

Sodium Thiosulfate 25% Solution for Injection

The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml

Sponsors & Collaborators

  • Hellenic Institute for the Study of Sepsis

    lead OTHER

Principal Investigators

  • Ioannis Alamanos, MD · General Hospital of Athens KAT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05277285 on ClinicalTrials.gov